Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease

J F Colombel, P Rutgeerts, H Malchow, M Jacyna, O H Nielsen, J Rask-Madsen, S Van Deventer, A Ferguson, P Desreumaux, A Forbes, K Geboes, L Melani, M Cohard

Research output: Contribution to journalArticlepeer-review

219 Citations (Scopus)


New lesions of Crohn's disease occur early after ileal or ileocolonic resection and ileocolonic anastomosis. We performed a double blind controlled trial to evaluate the safety and tolerance of recombinant human interleukin 10 (IL-10; Tenovil) in subjects operated on for Crohn's disease. We also assessed the effect of Tenovil in preventing endoscopic recurrence 12 weeks after surgery.
Original languageEnglish
Pages (from-to)42-46
Number of pages5
Issue number1
Publication statusPublished - Jul 2001


  • Adult
  • Chemotherapy, Adjuvant
  • Colonoscopy
  • Crohn Disease
  • Double-Blind Method
  • Electrophoresis, Agar Gel
  • Female
  • Hematocrit
  • Hemoglobins
  • Humans
  • Interleukin-1
  • Interleukin-10
  • Intestinal Mucosa
  • Male
  • Patient Compliance
  • Recurrence
  • Reverse Transcriptase Polymerase Chain Reaction
  • Statistics, Nonparametric
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha

Cite this